Juvenile myasthenia gravis may be more common than believed
A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly…
Articles by Marisa Wexler, MS
Kyverna planning to launch Phase 3 trial of KYV-101 in MG patients
Kyverna Therapeutics is planning to launch a Phase 3 clinical trial testing its experimental cell therapy KYV-101 in…
Cartesian launching 2 clinical trials testing Descartes-08 in MG
Cartesian Therapeutics is gearing up for two clinical trials of its cell therapy Descartes-08: the first, a Phase…
2 new home treatment methods for Rystiggo approved in Japan
Japan’s drug regulatory agency has authorized two new administration methods for Rystiggo (rozanolixizumab) — an approved treatment for…
Enrollment complete in Phase 2 trial testing DNTH103 for gMG
Enrollment is now complete for a Phase 2 clinical trial testing Dianthus Therapeutics‘ treatment candidate DNTH103 in people with…
Anti-MuSK antibody levels don’t reflect MG disease severity: Study
Levels of antibodies against muscle-specific kinase (MuSK) are not reflective of disease severity in people with MuSK-positive myasthenia gravis…
Symptoms of gMG controlled with long-term nipocalimab treatment
Long-term treatment with nipocalimab led to sustained reductions in symptom severity among antibody-positive patients with generalized myasthenia gravis…
Long-term benefits seen with Descartes-08 treatment in MG
Treatment with the cell therapy Descartes-08 led to long-term reductions in symptom severity for people with myasthenia gravis…
Scientists develop assay to detect anti-agrin antibodies in MG
Scientists in Korea have developed a cell-based test that can be used to detect antibodies against agrin, a protein involved…
MGFA patient conference highlights wellness education, science
More than 500 members of the myasthenia gravis (MG) community are expected at a conference featuring strategies for patient education,…